Repatha® (evolocumab) – New and expanded indications
December 1, 2017 – Amgen announced the FDA approval of Repatha (evolocumab) to reduce the risk of myocardial infarction (MI), stroke, and coronary revascularization in adults with established cardiovascular disease (CVD).
Download PDF
